RNA News and Research RSS Feed - RNA News and Research

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.
EnGeneIC closes oversubscribed Series B financing

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing. [More]
Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars. [More]
UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell's 'biological clock' to kill cancer cells and shrink tumor growth. [More]
FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Roche today announced that the U.S. Food and Drug Administration has provided an Emergency Use Authorization (EUA) for the LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West Africa. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Retroviruses are best known for causing contagious scourges such as AIDS, or more sporadically, cancer. [More]
Researchers identify new genetic anomalies in smoking-related lung cancers

Researchers identify new genetic anomalies in smoking-related lung cancers

Developing effective treatments for lung cancer has been challenging, in part because so many genetic mutations play a role in the disease. [More]
Endogenous retroviruses also play critical role in the body's immune defense against pathogens

Endogenous retroviruses also play critical role in the body's immune defense against pathogens

Retroviruses are best known for causing contagious scourges such as AIDS, or more sporadically, cancer. [More]
Researchers gain new insight into how motor neurons in the brain die during ALS

Researchers gain new insight into how motor neurons in the brain die during ALS

Researchers look to understand the causes of amyotrophic lateral sclerosis (ALS), in the hope of finding new ways to treat the disease. A new study published online today (December 17th) in the Cell Press journal Neuron shows that a common gene mutation in ALS generates a deadly protein that may cause the damage in the brain that leads to ALS. [More]
Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition. [More]
UTSA receives NIH grant to develop bioinformatics tools to find cause of breast cancer

UTSA receives NIH grant to develop bioinformatics tools to find cause of breast cancer

According to the American Cancer Society, breast cancer is the most common cancer among American women, except for skin cancers, and about one in eight women in the United States will develop invasive breast cancer during their lifetime. The National Institutes of Health recently awarded a $1.08 million grant to The University of Texas at San Antonio to combine computational modeling with biological information to advance our understanding of what may cause breast cells to become cancerous. [More]
Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals, Inc. announced today that it has initiated a study for ISIS-DMPK Rx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA. [More]
Study provides evidence for presence of enterovirus in pancreatic islets of type 1 diabetic patients

Study provides evidence for presence of enterovirus in pancreatic islets of type 1 diabetic patients

Norwegian scientists with European partners have found evidence for the presence of Enterovirus in pancreatic islets of type 1 diabetic patients. This provides evidence consistent with the theory that a low grade Enteroviral infection in the pancreatic islets contribute to disease progression in humans. [More]
Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings. [More]
New MIT study implicates RNA-binding proteins in regulation of cancer

New MIT study implicates RNA-binding proteins in regulation of cancer

A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation. [More]
Novel marker may help doctors choose most effective treatment for older patients with AML

Novel marker may help doctors choose most effective treatment for older patients with AML

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). [More]
TGen uncovers way to track cause of neurological disorder in a young girl

TGen uncovers way to track cause of neurological disorder in a young girl

Using a basic genetic difference between men and women, the Translational Genomics Research Institute has uncovered a way to track down the source of a neurological disorder in a young girl. [More]
New technique allows rapid, large-scale studies of gene function

New technique allows rapid, large-scale studies of gene function

Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells. [More]
Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL). [More]
CRISPR/Cas9 genome editing: an interview with Maja Petkovic

CRISPR/Cas9 genome editing: an interview with Maja Petkovic

RNA guided CRISPR nucleases have a great potential for genome modification in many different organisms. [More]